The Share

The Diamyd Medical share is traded on Nasdaq First North Growth Market (ticker : DMYD B). ISIN code: SE0005162880.

About Nasdaq First North Growth Market

Nasdaq First North Growth Market is an alternative marketplace operated by an exchange within the Nasdaq Group. Companies on Nasdaq First North Growth Market are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on Nasdaq First North Growth Market may therefore be higher than investing in a company on the main market. All companies with shares traded on Nasdaq First North Growth Market have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at Nasdaq First North Growth Market

FNCA Sweden AB, Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm. Tel: 08-528 00 399, E-mail: info@fnca.se.

Annual Report

  December 17, 2019

Company Presentation

CEO Comments

Read More
  Financial Statement 19/20, October 7, 2020

Dear Shareholders and readers

On September 14 we had the pleasure to announce the topline results from DIAGNODE-2, the European multicenter Phase IIb trial in 109 individuals recently diagnosed with type 1 diabetes. The results show, in line with comprehensive insights from previous trials and scientific publications, that the diabetes vaccine Diamyd® (GAD-alum) has a positive and significant disease-modifying effect on the preservation of endogenous insulin production compared to placebo in a genetically...

The focus forward into Phase III and beyond is aligned with genetics-based Precision Medicine - targeting the right individual with the right treatment at the right time.
Ulf Hannelius, President and CEO

Calendar

  
Data pager
Data pager
12
November 5, 2020
Annual Report
Annual Report 2019/2020
November 26, 2020
Annual General Meeting
Annual General Meeting 2019/2020
January 20, 2021
Quarterly Report I
Quarterly Report 1 2020/2021
March 31, 2021
Quarterly Report II
Quarterly Report 2 2020/2021
 

We are dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technologies

 

Ten largest shareholders as of September 30, 2020

ShareholderA SharesB SharesCapital %Votes %
Avanza Pension 9 050 544 13.08 9.82
Essen-Möller, Anders 2 556 223 6 333 040 12.85 34.60
Lindkvist, Bertil 6 500 000 9.40 7.05
Nordnet Pension 2 285 303 3.30 2.48
Swedbank Försäkring 844 899 1.22 0.92
Konstruktions o Försäljningsaktiebolag 750 745 1.09 0.81
Arandi Development AB 514 000 0.74 0.56
Relbo AB 475 550 0.69 0.52
Lindberg, Mikael 460 021 0.67 0.50
Schelé, Sven 460 000 0.67 0.50
Remaining shareholders 38 939 471 56.30 42.24
Total 2 556 223 66 613 573 100.0 100.0

Order GAD for preclinical research

ORDER

Annual Report

  December 17, 2019
Annual Report cover image
Download

Contact Us

Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden
+46 8 661 00 26
+46 8 661 63 68

Subscribe

   

Follow Us

  ©
GAD PRODUCTS
Order GAD for preclinical research